MedTrace Logo

A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC

NCT02860546 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2024-09-03

Study results available
· View outcomes & findings →

Summary

A Phase 2 Study with Safety Lead-in, Evaluating TAS-102 Plus Nivolumab in Participants with Microsatellite Stable Refractory Metastatic Colorectal Cancer

Conditions

  • Refractory Metastatic Colorectal Cancer

Interventions

DRUG

TAS-102

One Arm Only (of TAS 102 plus nivolumab)

DRUG

nivolumab

One Arm Only (of TAS 102 plus nivolumab)

Sponsors & Collaborators

  • Taiho Oncology, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-29
Primary Completion
2017-08-31
Completion
2017-09-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02860546 on ClinicalTrials.gov